Indeed, Xu et al. obtained CD59 mRNA levels were determined by real-time PCR in matched (tumor/normal) microdissected tissues from 26 cases and they found that: “High rates of CD59 expression were noted in 36% of prostate cancer cases and were significantly associated with tumor pT stage (P = 0.043), Gleason grade (P = 0.013) and earlier biochemical (PSA) relapse in Kaplan-Meier analysis (P = 0.0013). The gene discussed is CD59; the disease is prostate cancer.